Literature DB >> 30514106

SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells.

Giovanna Sociali1, Alessia Grozio1, Irene Caffa2, Susanne Schuster3, Pamela Becherini2, Patrizia Damonte2, Laura Sturla1, Chiara Fresia1, Mario Passalacqua1, Francesca Mazzola4, Nadia Raffaelli5, Antje Garten3,6, Wieland Kiess3, Michele Cea2,7, Alessio Nencioni2,7, Santina Bruzzone1,8.   

Abstract

Nicotinamide phosphoribosyltransferase (NAMPT) is the rate-limiting enzyme in the NAD+ salvage pathway from nicotinamide. By controlling the biosynthesis of NAD+, NAMPT regulates the activity of NAD+-converting enzymes, such as CD38, poly-ADP-ribose polymerases, and sirtuins (SIRTs). SIRT6 is involved in the regulation of a wide number of metabolic processes. In this study, we investigated the ability of SIRT6 to regulate intracellular NAMPT activity and NAD(P)(H) levels. BxPC-3 cells and MCF-7 cells were engineered to overexpress a catalytically active or a catalytically inactive SIRT6 form or were engineered to silence endogenous SIRT6 expression. In SIRT6-overexpressing cells, NAD(H) levels were up-regulated, as a consequence of NAMPT activation. By immunopurification and incubation with recombinant SIRT6, NAMPT was found to be a direct substrate of SIRT6 deacetylation, with a mechanism that up-regulates NAMPT enzymatic activity. Extracellular NAMPT release was enhanced in SIRT6-silenced cells. Also glucose-6-phosphate dehydrogenase activity and NADPH levels were increased in SIRT6-overexpressing cells. Accordingly, increased SIRT6 levels reduced cancer cell susceptibility to H2O2-induced oxidative stress and to doxorubicin. Our data demonstrate that SIRT6 affects intracellular NAMPT activity, boosts NAD(P)(H) levels, and protects against oxidative stress. The use of SIRT6 inhibitors, together with agents inducing oxidative stress, may represent a promising treatment strategy in cancer.-Sociali, G., Grozio, A., Caffa, I., Schuster, S., Becherini, P., Damonte, P., Sturla, L., Fresia, C., Passalacqua, M., Mazzola, F., Raffaelli, N., Garten, A., Kiess, W., Cea, M., Nencioni, A., Bruzzone, S. SIRT6 deacetylase activity regulates NAMPT activity and NAD(P)(H) pools in cancer cells.

Entities:  

Keywords:  Sirtuin 6; nicotinamide adenine dinucleotide; nicotinamide phosphoribosyltransferase

Mesh:

Substances:

Year:  2018        PMID: 30514106      PMCID: PMC6988859          DOI: 10.1096/fj.201800321R

Source DB:  PubMed          Journal:  FASEB J        ISSN: 0892-6638            Impact factor:   5.191


  56 in total

1.  Kinetic and Structural Basis for Acyl-Group Selectivity and NAD(+) Dependence in Sirtuin-Catalyzed Deacylation.

Authors:  Jessica L Feldman; Kristin E Dittenhafer-Reed; Norio Kudo; Julie N Thelen; Akihiro Ito; Minoru Yoshida; John M Denu
Journal:  Biochemistry       Date:  2015-05-04       Impact factor: 3.162

2.  SIRT1-Mediated eNAMPT Secretion from Adipose Tissue Regulates Hypothalamic NAD+ and Function in Mice.

Authors:  Myeong Jin Yoon; Mitsukuni Yoshida; Sean Johnson; Akiko Takikawa; Isao Usui; Kazuyuki Tobe; Takashi Nakagawa; Jun Yoshino; Shin-ichiro Imai
Journal:  Cell Metab       Date:  2015-04-23       Impact factor: 27.287

3.  Mitochondrial superoxide mediates doxorubicin-induced keratinocyte apoptosis through oxidative modification of ERK and Bcl-2 ubiquitination.

Authors:  Sudjit Luanpitpong; Pithi Chanvorachote; Ubonthip Nimmannit; Stephen S Leonard; Christian Stehlik; Liying Wang; Yon Rojanasakul
Journal:  Biochem Pharmacol       Date:  2012-03-24       Impact factor: 5.858

Review 4.  SIRT6: Novel Mechanisms and Links to Aging and Disease.

Authors:  Luisa Tasselli; Wei Zheng; Katrin F Chua
Journal:  Trends Endocrinol Metab       Date:  2016-11-09       Impact factor: 12.015

5.  The NAD biosynthesis pathway mediated by nicotinamide phosphoribosyltransferase regulates Sir2 activity in mammalian cells.

Authors:  Javier R Revollo; Andrew A Grimm; Shin-ichiro Imai
Journal:  J Biol Chem       Date:  2004-09-20       Impact factor: 5.157

Review 6.  Nicotinamide phosphoribosyltransferase (NAMPT) inhibitors as therapeutics: rationales, controversies, clinical experience.

Authors:  Fabrizio Montecucco; Michele Cea; Inga Bauer; Debora Soncini; Irene Caffa; Denise Lasigliè; Aimable Nahimana; Antonio Uccelli; Santina Bruzzone; Alessio Nencioni
Journal:  Curr Drug Targets       Date:  2013-06-01       Impact factor: 3.465

7.  Cyclic ADP-ribose is a second messenger in the lipopolysaccharide-stimulated proliferation of human peripheral blood mononuclear cells.

Authors:  Santina Bruzzone; Antonio De Flora; Cesare Usai; Richard Graeff; Hon Cheung Lee
Journal:  Biochem J       Date:  2003-10-15       Impact factor: 3.857

8.  A Nampt inhibitor FK866 mimics vitamin B3 deficiency by causing senescence of human fibroblastic Hs68 cells via attenuation of NAD(+)-SIRT1 signaling.

Authors:  Tuzz-Ying Song; Shu-Lan Yeh; Miao-Lin Hu; Mei-Yau Chen; Nae-Cherng Yang
Journal:  Biogerontology       Date:  2015-09-02       Impact factor: 4.277

9.  Reactive oxygen species mediate doxorubicin induced p53-independent apoptosis.

Authors:  W P Tsang; Sophia P Y Chau; S K Kong; K P Fung; T T Kwok
Journal:  Life Sci       Date:  2003-09-05       Impact factor: 5.037

10.  Resveratrol differentially regulates NAMPT and SIRT1 in Hepatocarcinoma cells and primary human hepatocytes.

Authors:  Susanne Schuster; Melanie Penke; Theresa Gorski; Stefanie Petzold-Quinque; Georg Damm; Rolf Gebhardt; Wieland Kiess; Antje Garten
Journal:  PLoS One       Date:  2014-03-06       Impact factor: 3.240

View more
  24 in total

1.  SIRT6 enhances oxidative phosphorylation in breast cancer and promotes mammary tumorigenesis in mice.

Authors:  Pamela Becherini; Irene Caffa; Francesco Piacente; Patrizia Damonte; Valerio G Vellone; Mario Passalacqua; Andrea Benzi; Tommaso Bonfiglio; Daniele Reverberi; Amr Khalifa; Moustafa Ghanem; Ana Guijarro; Luca Tagliafico; Marzia Sucameli; Angelica Persia; Fiammetta Monacelli; Michele Cea; Santina Bruzzone; Silvia Ravera; Alessio Nencioni
Journal:  Cancer Metab       Date:  2021-01-22

Review 2.  Subcellular compartmentalization of NAD+ and its role in cancer: A sereNADe of metabolic melodies.

Authors:  Yi Zhu; Jiaqi Liu; Joun Park; Priyamvada Rai; Rong G Zhai
Journal:  Pharmacol Ther       Date:  2019-04-08       Impact factor: 12.310

Review 3.  NAD+ metabolism and its roles in cellular processes during ageing.

Authors:  Anthony J Covarrubias; Rosalba Perrone; Alessia Grozio; Eric Verdin
Journal:  Nat Rev Mol Cell Biol       Date:  2020-12-22       Impact factor: 94.444

Review 4.  Nuclear metabolism and the regulation of the epigenome.

Authors:  Ruben Boon; Giorgia G Silveira; Raul Mostoslavsky
Journal:  Nat Metab       Date:  2020-10-12

Review 5.  Immunometabolism during Mycobacterium tuberculosis Infection.

Authors:  Nicole C Howard; Shabaana A Khader
Journal:  Trends Microbiol       Date:  2020-05-11       Impact factor: 17.079

Review 6.  NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential.

Authors:  Na Xie; Lu Zhang; Wei Gao; Canhua Huang; Peter Ernst Huber; Xiaobo Zhou; Changlong Li; Guobo Shen; Bingwen Zou
Journal:  Signal Transduct Target Ther       Date:  2020-10-07

Review 7.  Is nuclear sirtuin SIRT6 a master regulator of immune function?

Authors:  Vinodkumar B Pillai; Mahesh P Gupta
Journal:  Am J Physiol Endocrinol Metab       Date:  2020-12-14       Impact factor: 4.310

Review 8.  Emerging roles of SIRT6 in human diseases and its modulators.

Authors:  Gang Liu; Haiying Chen; Hua Liu; Wenbo Zhang; Jia Zhou
Journal:  Med Res Rev       Date:  2020-12-16       Impact factor: 12.944

9.  Relationship between NAMPT/PBEF/visfatin and prognosis of patients with malignant tumors: a systematic review and meta-analysis.

Authors:  Chengjian Ji; Rong Cong; Yi Wang; Yamin Wang; Qijie Zhang; Xiang Zhou; Qianwei Xing; Ninghong Song
Journal:  Ann Transl Med       Date:  2019-12

10.  CTRP13 Mitigates Abdominal Aortic Aneurysm Formation via NAMPT1.

Authors:  Wenjing Xu; Yuelin Chao; Minglu Liang; Kai Huang; Cheng Wang
Journal:  Mol Ther       Date:  2020-09-06       Impact factor: 11.454

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.